glp-1 agonists marketing strategies 2025 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 Glucagon-Like Peptide 1 (GLP-1) Agonist

Epithalon has demonstrated significant immunomodulatory properties in research settings, including restoration of T-lymphocyte activity, improved NK cell function, and normalization of cytokine profiles

The deficiency was more severe than expected People with advanced B12 deficiency, especially with neurological symptoms, often feel rough at the start of treatment because the underlying problem was significant

Detoxification Thyroid patients, especially those with Hashimotos, are susceptible to endocrine-disrupting chemicals

Obesity is a risk factor for numerous health conditions, including diabetes, high blood pressure, high cholesterol and sleep apnea

The TRIUMPH program has more Phase 3 readouts expected through 2026